blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2900240

EP2900240 - CRYSTALLINE FORM OF A REVERSE TRANSCRIPTASE INHIBITOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.11.2020
Database last updated on 12.07.2024
FormerThe patent has been granted
Status updated on  06.12.2019
FormerGrant of patent is intended
Status updated on  31.07.2019
FormerExamination is in progress
Status updated on  03.03.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
[2015/32]
Inventor(s)01 / MAGUIRE, Courtney, K.
126 East Lincoln Avenue
Rahway, New Jersey 07065-0907 / US
 [2015/32]
Representative(s)Jaap, David Robert, et al
Merck Sharp & Dohme Corp.
120 Moorgate
London, EC2M 6UR / GB
[N/P]
Former [2015/32]Jaap, David Robert, et al
Merck & Co., Inc.
Patent Department
Hertford Road
Hoddesdon, Herts EN11 9BU / GB
Application number, filing date13840379.520.09.2013
[2020/02]
WO2013US60787
Priority number, dateUS201261705780P26.09.2012         Original published format: US 201261705780 P
[2015/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014052171
Date:03.04.2014
Language:EN
[2014/14]
Type: A1 Application with search report 
No.:EP2900240
Date:05.08.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 03.04.2014 takes the place of the publication of the European patent application.
[2015/32]
Type: B1 Patent specification 
No.:EP2900240
Date:08.01.2020
Language:EN
[2020/02]
Search report(s)International search report - published on:US03.04.2014
(Supplementary) European search report - dispatched on:EP15.06.2016
ClassificationIPC:C07D401/06, A61K31/4439
[2016/28]
CPC:
C07D401/06 (EP,US); A61K31/4439 (EP,US); A61P31/18 (EP);
A61P43/00 (EP)
Former IPC [2015/32]A61K31/4439
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/32]
Extension statesBA28.04.2015
ME28.04.2015
TitleGerman:KRISTALLINE FORM EINES REVERSE-TRANSKRIPTASE-INHIBITORS[2015/32]
English:CRYSTALLINE FORM OF A REVERSE TRANSCRIPTASE INHIBITOR[2015/32]
French:FORME CRISTALLINE D'INHIBITEUR DE TRANSCRIPTASE INVERSE[2015/32]
Entry into regional phase28.04.2015National basic fee paid 
28.04.2015Search fee paid 
28.04.2015Designation fee(s) paid 
28.04.2015Examination fee paid 
Examination procedure28.04.2015Examination requested  [2015/32]
10.01.2017Amendment by applicant (claims and/or description)
01.03.2017Despatch of a communication from the examining division (Time limit: M06)
07.09.2017Reply to a communication from the examining division
12.12.2017Despatch of a communication from the examining division (Time limit: M06)
20.06.2018Reply to a communication from the examining division
01.08.2019Communication of intention to grant the patent
28.11.2019Fee for grant paid
28.11.2019Fee for publishing/printing paid
28.11.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  01.03.2017
Opposition(s)09.10.2020No opposition filed within time limit [2020/51]
Fees paidRenewal fee
08.09.2015Renewal fee patent year 03
08.09.2016Renewal fee patent year 04
11.09.2017Renewal fee patent year 05
11.09.2018Renewal fee patent year 06
11.09.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.09.2013
AL08.01.2020
AT08.01.2020
CY08.01.2020
CZ08.01.2020
DK08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
MC08.01.2020
MK08.01.2020
MT08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
IE20.09.2020
LU20.09.2020
BE30.09.2020
[2022/31]
Former [2022/30]HU20.09.2013
AL08.01.2020
AT08.01.2020
CY08.01.2020
CZ08.01.2020
DK08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
MC08.01.2020
MT08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
IE20.09.2020
LU20.09.2020
BE30.09.2020
Former [2022/27]HU20.09.2013
AT08.01.2020
CY08.01.2020
CZ08.01.2020
DK08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
MC08.01.2020
MT08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
IE20.09.2020
LU20.09.2020
BE30.09.2020
Former [2021/37]AT08.01.2020
CZ08.01.2020
DK08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
MC08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
IE20.09.2020
LU20.09.2020
BE30.09.2020
Former [2021/36]AT08.01.2020
CZ08.01.2020
DK08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
MC08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
LU20.09.2020
BE30.09.2020
Former [2021/27]AT08.01.2020
CZ08.01.2020
DK08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
MC08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
LU20.09.2020
Former [2021/23]AT08.01.2020
CZ08.01.2020
DK08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
MC08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2021/11]AT08.01.2020
CZ08.01.2020
DK08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
PL08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SI08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/50]CZ08.01.2020
DK08.01.2020
EE08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/49]CZ08.01.2020
DK08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SK08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/48]DK08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RO08.01.2020
RS08.01.2020
SE08.01.2020
SM08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/47]DK08.01.2020
FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RS08.01.2020
SE08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/40]FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RS08.01.2020
SE08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
IS08.05.2020
PT31.05.2020
Former [2020/39]FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RS08.01.2020
SE08.01.2020
BG08.04.2020
NO08.04.2020
GR09.04.2020
PT31.05.2020
Former [2020/38]FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RS08.01.2020
SE08.01.2020
NO08.04.2020
GR09.04.2020
PT31.05.2020
Former [2020/37]FI08.01.2020
HR08.01.2020
LT08.01.2020
LV08.01.2020
RS08.01.2020
SE08.01.2020
NO08.04.2020
PT31.05.2020
Former [2020/36]FI08.01.2020
LT08.01.2020
RS08.01.2020
NO08.04.2020
PT31.05.2020
Former [2020/35]FI08.01.2020
LT08.01.2020
NO08.04.2020
Documents cited:Search[Y]WO2011120133  (MERCK FROSST CANADA LTD [CA], et al) [Y] 1-4 * examples 1, 1A *;
 [Y]  - CAIRA M R, "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, (19980101), vol. 198, doi:10.1007/3-540-69178-2_5, ISSN 0340-1022, pages 163 - 208, XP001156954 [Y] 1-4 * the whole document *

DOI:   http://dx.doi.org/10.1007/3-540-69178-2_5
International search[Y]US2005222134  (BUSACCA CARL A [US], et al);
 [Y]US2011245296  (BURCH JASON [US], et al);
 [Y]WO2011126969  (MERCK SHARP & DOHME [US], et al)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.